Zepbound Injection Sites: Where to Inject Tirzepatide and Semaglutide, and Why to Rotate

Quick answer

As of September 2026, the FDA-approved labels for Zepbound, Mounjaro, Wegovy and Ozempic all list the same three injection areas: the abdomen, the thigh and the upper arm. Each of these labels asks that the injection site be rotated with each dose, and the tirzepatide and semaglutide labels both state that similar exposure was achieved from all three areas, so the label does not rank one Zepbound injection site above another, and the GLP-1 injection sites are the same across all four products. The area a person can reach comfortably and rotate within, chosen with the prescriber, is the one to use.

Does the injection site change how much medicine reaches the blood?

The Clinical Pharmacology section of the Zepbound label prints: "Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm." The Mounjaro label carries the identical sentence, so the tirzepatide injection sites on both labels are listed without preference, and the Wegovy label prints the same statement for semaglutide. The Ozempic label states it in the present tense: "Similar exposure is achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm."

Exposure is a pharmacology word for how much of a medicine reaches the blood and how long it stays there after a dose. When a label says exposure was similar across three areas, the studies behind the label did not find that one area delivered more medicine than another.

The Wegovy label adds, in its Dosage and Administration section: "The time of day and the injection site can be changed without the need for a dosage modification." For Wegovy, then, moving from the thigh to the abdomen is not by itself a reason for a dosage change. The Zepbound label does not print an equivalent sentence, so a person who wants to change their routine asks the prescriber first. The practical question is therefore which area a person can reach, see clearly, keep clean and rotate within.

Where to inject Zepbound or tirzepatide: which area should I choose?

The Zepbound label states it in one sentence: "Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose." The Mounjaro label uses the same wording for MOUNJARO. Where to inject semaglutide is answered the same way. The Wegovy label reads: "Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm." The Ozempic label uses the same three-area list.

Each is an FDA-approved product with its own indication on its label. Which medicine, if any, is appropriate for a given person is a decision for a licensed physician.

The abdomen. The Zepbound Instructions for Use list the stomach (abdomen) as an area a person can inject alone or with help. The Wegovy Instructions for Use print an exact distance to keep away from the navel; the figure is in the leaflet, and its purpose is to keep the injection away from the tissue immediately around the belly button.

The thigh. The Wegovy Instructions for Use describe the front of the thigh. It gives a second area to alternate with the abdomen.

The back of the upper arm. Here the tirzepatide labels are specific: another person should give the injection. The Wegovy and Ozempic Instructions for Use say the same in their own words, listing "back of upper arm (only with help from someone else)". The Zepbound Instructions for Use say that another person should give the injection in the back of the upper arm, so a caregiver or family member who has been shown the technique gives it there. A person who injects alone has the abdomen and the thigh.

The Zepbound Instructions for Use put the choice where it belongs: the healthcare provider can help choose the injection site.

Why do the labels ask me to rotate?

Rotation is a label instruction with a stated reason. The Zepbound Instructions for Use print: "Change (rotate) your injection site within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites." The Mounjaro Instructions for Use carry the same sentence.

The label explains both terms in its own parentheses: lipodystrophy as pits in skin or thickened skin, and localized cutaneous amyloidosis as skin with lumps. Both are described as changes at the injection sites, which is why the instruction is to rotate.

There is a long record of this in insulin care. Injection technique recommendations published in Mayo Clinic Proceedings in 2016 by an international group of diabetes experts state in the abstract that "lipohypertrophy is a frequent complication of therapy that distorts insulin absorption, and, therefore, injections and infusions should not be given into these lesions and correct site rotation will help prevent them". Those recommendations were written for insulin injections, not for tirzepatide or semaglutide. They are cited here because the GLP-1 labels carry the same instruction to rotate, and because the abstract names a second reason: thickened tissue changes how a medicine is absorbed from that spot.

What does a rotation habit look like?

The labels distinguish between an area and a spot. The Wegovy Instructions for Use allow the same body area as long as the spot moves: "Avoid using the exact same spot as the last time between injections." The Zepbound Instructions for Use ask you to change the site "within the area you choose for each dose". The Ozempic Medication Guide puts it as: "Change (rotate) your injection site with each injection. Do not use the same site for each injection."

What the labels ask for, in words only: the same body area may be used again, as the Zepbound Instructions for Use put it, "You may use the same area of your body but be sure to choose a different injection site in that area." The pattern a person follows within that area, and how far apart the spots should be, is for the prescriber or pharmacist who teaches the technique; the Wegovy leaflet prints one distance to keep from the navel, and this page does not reproduce it.

What skin should I avoid?

Both manufacturers print a list. The Zepbound Instructions for Use: "Do not inject where the skin has pits, is thickened, or has lumps. Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin." The Wegovy Instructions for Use: "Do not inject into an area where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks."

Read together, the rule is short. Healthy, intact, unbruised skin only. Not into a bruise from the last injection, not into a scar, not into stretch marks, not into a spot that already feels hard or lumpy. If a spot looks or feels different from the skin around it, pick another spot. For people who use more than one injectable, the Zepbound Instructions for Use add: "Do not inject ZEPBOUND in the same injection site used for other medicines."

What do the Instructions for Use cover?

The step by step technique belongs to the Instructions for Use packed with the product and to the prescriber or pharmacist who demonstrates it. Storage is a separate question, answered from the Zepbound, Mounjaro and Wegovy labels in does Zepbound need to be refrigerated. This page describes where to inject and why rotation matters; it does not teach the technique and prints no figures from the leaflet. If you are looking for how to inject Zepbound or how to inject tirzepatide step by step, the leaflet packed with your product and a demonstration by the prescriber or pharmacist are the answer. What the Zepbound and Wegovy Instructions for Use have in common, described here and not taught: both leaflets begin with choosing the injection site with the healthcare provider, both ask for clean hands and clean, dry skin at the site (the Wegovy leaflet says "Clean the injection site with an alcohol swab or soap and water" and "Do not touch the injection site after cleaning. Allow the skin to dry before injecting."), and both end with the used pen or needle going into an FDA-cleared sharps disposal container right away after use rather than household trash. The injection itself, and everything between those points, is taught by the leaflet and the healthcare provider, not by this page.

Zepbound comes in more than one presentation. Its label tells prescribers to inform patients and caregivers which presentation they will receive, naming the vial, the prefilled single-dose pen and the single-patient-use KwikPen, and to make sure they are trained for that presentation. The label carries separate Instructions for Use documents for the single-dose pen, the single-dose vial, the multi-dose vial and the KwikPen; the vials are used with a syringe and needle. For the pen device, see how the Zepbound KwikPen works.

What changes with a compounded vial?

Compounded tirzepatide or compounded semaglutide usually comes as a vial that is drawn up with a syringe. Compounded medications are not FDA-approved as final products. That matters here for one reason: a compounded vial has no FDA-approved label of its own, so the instructions for that vial come from the dispensing pharmacy and from the prescriber, not from a leaflet in a manufacturer's carton.

What carries over is the anatomy. The three areas and the rotation instruction on this page come from the approved labels of products that contain tirzepatide and semaglutide, and the skin changes those labels warn about are changes in the skin, not in the product. What does not carry over is anything about volumes, units or how to fill the syringe; this page prints none of that. If the syringe markings are unfamiliar, how syringe units relate to a prescription explains how to read them. Two related questions are answered elsewhere: how long a compounded semaglutide vial stays usable and what is known about compounded tirzepatide.

Which injection site reactions do the labels list?

The Zepbound label names injection site reactions among the most common adverse reactions in its trials, and a footnote explains the term: "Includes multiple related adverse event terms, such as injection site bruising, injection site erythema, injection site pruritus, injection site pain, injection site rash, injection site reaction." The Wegovy label describes "injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation)."

In plain words: erythema is redness, pruritus is itching, induration is a firm or hardened patch, and inflammation is swelling with warmth. These are local reactions at the spot where the needle went in.

Both labels also describe hypersensitivity reactions, which are allergic-type reactions and a different category from a local skin reaction; the Zepbound label's instruction for a suspected serious reaction is to seek medical attention promptly.

For a local reaction that spreads, worsens or does not settle, contact the prescriber. This page offers no self-treatment advice, because the labels do not. A wider guide to the label's adverse reaction list is at Zepbound side effects.

Is there research on injection sites and body size?

At least one study is registered. ClinicalTrials.gov lists NCT04050670, titled "A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes." As of September 2026 the record shows the status as Completed, the study type as Interventional and the phase as Phase 1. Only the title, status and phase are reported here, as the registry prints them.

What not to do

• Do not inject into a bruise, a scar, stretch marks, or skin that is tender, red, hard, pitted, thickened or lumpy.
• Do not use the exact same spot each time. Rotate with each dose.
• Do not share pens or needles, even if the needle is changed; the labels carry this as a warning, and the KwikPen guide covers it.
• Do not reuse needles or syringes; the Zepbound vial Instructions for Use ask for a new syringe and needle for each injection.

Questions for a prescriber or pharmacist

• Which of the three areas suits me, given that I inject alone or with help?
• Can you show me the rotation pattern you want me to follow within that area?
• If I use a compounded vial, which written instructions do I follow, and who do I call if the syringe markings are unclear?
• What kind of injection site reaction should I report to you, and how soon?

Related reading: how to read a prescription label and what a GLP-1 medication is.

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Injection technique should be learned from the Instructions for Use packed with the product and from a prescriber or pharmacist.